Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
ESPERION reported Q1 2021 results, achieving total revenue of $8.0 million, up from $1.8 million in Q1 2020. U.S. product revenue reached $6.4 million, a significant increase from $0.9 million year-over-year. The company secured a major Medicare Part D contract covering 8.5 million lives and strengthened its balance sheet with $80 million from expanded agreements. However, ESPERION continues to face challenges, including a net loss of $90.9 million, rising expenses, and a lower net price impacting product demand.
Esperion (NASDAQ: ESPR) announced the granting of 50,991 restricted stock units (RSUs) to 21 new employees on April 23, 2021. This was executed under the 2017 Inducement Equity Incentive Plan, aimed at attracting individuals who have not previously worked for the company. Each RSU will vest incrementally, with 25% on the one-year anniversary and the remaining 75% in quarterly installments, contingent upon continued employment. This initiative underscores Esperion's commitment to building a robust team focused on lipid management.
Esperion (NASDAQ: ESPR) announced the peer-reviewed publication of the design of the CLEAR Outcomes trial, the first cardiovascular outcomes study focusing on patients intolerant to statins. The trial, fully enrolled with over 14,000 participants, is designed to assess the effectiveness of NEXLETOL in reducing major adverse cardiovascular events (MACE). Notably, nearly half of the participants are women, a significant increase compared to previous studies. Results are anticipated in the second half of 2022, with the trial aiming for a 15% relative risk reduction in MACE.
Esperion Therapeutics (NASDAQ: ESPR) has secured a third tranche of $50 million in funding from an investor group led by Oberland Capital Management, bringing total funding to $80 million. This funding is part of a revenue-based agreement that allows Esperion to regain 100% revenue rights after repayment. Additionally, the company announced an expansion of a commercial agreement in strategic non-U.S. markets. CFO Rick Bartram emphasized the financial benefits and confidence in Esperion's potential, underscoring its commitment to lipid management.
Esperion Therapeutics announced a licensing agreement with Daiichi Sankyo, granting exclusive rights to commercialize bempedoic acid and its combination tablet in select Asian, Middle Eastern, and Latin American countries. The deal includes a $30 million upfront payment and up to $175 million in milestone payments, contributing to a total of $1.1 billion in potential milestones. This partnership aims to strengthen market reach and address unmet cardiovascular needs globally. The terms allow Esperion to retain rights in several regions, including the U.S.
Esperion (NASDAQ: ESPR) will report its first quarter 2021 financial results after U.S. markets close on May 4, 2021. Management will host a conference call at 4:30 p.m. ET to discuss these results and business developments. The call can be accessed via a dedicated phone line or through a live audio webcast on their investor website. Esperion focuses on LDL-C management, providing oral medication to patients unable to reach cholesterol goals with current therapies. They emphasize the critical need for effective treatments in a substantial portion of the U.S. population.
Esperion (NASDAQ: ESPR) announced that CEO Tim M. Mayleben will participate in an analyst-led fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 9:30 a.m. ET. The event will include a live audio webcast, accessible via the company's investor relations website, and a replay will be available for 90 days post-event. Esperion aims to develop new LDL-C lowering medicines to combat cardiovascular disease, which affects over 96 million adults in the U.S.
Esperion announced positive results from a Phase 2 study published in Atherosclerosis, evaluating the combination of NEXLETOL (bempedoic acid), ezetimibe, and atorvastatin in hypercholesterolemia patients. The triple therapy resulted in a 60.5% reduction in LDL-C levels compared to placebo, with over 90% of patients achieving LDL-C levels 70 mg/dL. Despite these promising results, the small sample size and brief duration limit the study's conclusions. Adverse events were mostly mild to moderate, affirming the need for more research to confirm long-term effects.
ESPERION reported significant growth in its fourth quarter 2020, with total revenue reaching $9.6 million, a substantial increase from $1.0 million in Q4 2019. U.S. product revenue for the same period was $8.2 million, marking a 150% increase from Q3 2020. The company has over 21,000 patients on its NEXLETOL® and NEXLIZET® medications. Despite a net loss of $104.5 million for Q4 2020, the balance sheet remains strong with $305.0 million in cash and cash equivalents. Looking ahead, expected operating expenses for 2021 range from $320 million to $340 million.
Esperion (NASDAQ: ESPR) will announce its fourth quarter and full year 2020 financial results on February 23, 2021. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and business progress. The call is accessible domestically at (877) 831-3840 and internationally at (253) 237-1184 with access code 2689156. A live audio webcast will also be available on Esperion's investor website, along with a replay accessible for 90 days.